Literature DB >> 28599436

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer.

Xiao-Chuan Ge1, Fan Wu1, Wei-Tao Li1, Xuan-Jin Zhu1, Jian-Wei Liu1, Bai-Lin Wang1.   

Abstract

WEE1 is a serine/threonine protein kinase that inactivates cell division cycle 2 and is therefore a critical cell cycle regulator. Increased WEE1 expression has been observed in numerous types of human malignancies, including hepatocellular carcinoma and melanoma. WEE1 inhibition also results in evident anti-tumor effects in several human tumor cells including colon cancer cells, suggesting WEE1 as a potential therapeutic target for the treatment of cancer. However, the expression pattern of WEE1 in colorectal cancer (CRC) remains unclear. In the present study, WEE1 mRNA expression in 43 cases of CRC tissues matched with adjacent normal tissues was determined by reverse-transcription quantitative polymerase chain reaction. The results demonstrated that WEE1 mRNA expression was significantly increased in CRC tissues and that this upregulation correlated significantly with hepatic metastasis, distant metastasis and high tumor node metastasis (TNM) stage of CRC. Additionally, WEE1 protein in 102 CRC tissue samples was detected by immunohistochemistry, and positive staining of WEE1 was identified in more than half of patients with CRC. WEE1 staining scores were also observed to be associated with distant metastasis and high TNM stage of CRC. In addition, patients with CRC with high WEE1 staining score (2+ or 3+) exhibited either poorer overall survival or poorer disease-free survival compared with those with low WEE1 staining score (0 or 1+). The multivariable Cox model also identified a high WEE1 staining score as well as high TNM stage to be independent prognostic factors for CRC. In conclusion, WEE1 upregulation is associated with a high degree of malignancy and poor prognosis of CRC, suggesting WEE1 as a potential prognostic biomarker for CRC.

Entities:  

Keywords:  WEE1; colorectal cancer; immunohistochemistry; prognosis; quantitative polymerase chain reaction

Year:  2017        PMID: 28599436      PMCID: PMC5453116          DOI: 10.3892/ol.2017.5984

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15.

Authors:  P R Mueller; T R Coleman; A Kumagai; W G Dunphy
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

Review 2.  G2 checkpoint abrogators as anticancer drugs.

Authors:  Takumi Kawabe
Journal:  Mol Cancer Ther       Date:  2004-04       Impact factor: 6.261

3.  Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

Authors:  Ana Slipicevic; Arild Holth; Ellen Hellesylt; Claes G Tropé; Ben Davidson; Vivi Ann Flørenes
Journal:  Gynecol Oncol       Date:  2014-08-02       Impact factor: 5.482

4.  Mutants altered in the control co-ordinating cell division with cell growth in the fission yeast Schizosaccharomyces pombe.

Authors:  P Thuriaux; P Nurse; B Carter
Journal:  Mol Gen Genet       Date:  1978-05-03

5.  Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.

Authors:  Lyndsay M Murrow; Sireesha V Garimella; Tamara L Jones; Natasha J Caplen; Stanley Lipkowitz
Journal:  Breast Cancer Res Treat       Date:  2009-10-10       Impact factor: 4.872

6.  Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma.

Authors:  Fan Wu; Si-Yu Liu; Yi-Ming Tao; Di-Peng Ou; Feng Fang; Lian-Yue Yang
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

7.  High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.

Authors:  Gry Irene Magnussen; Ruth Holm; Elisabeth Emilsen; Anne Katrine Ree Rosnes; Ana Slipicevic; Vivi Ann Flørenes
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

8.  Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

Authors:  Elizabeth Iorns; Christopher J Lord; Anita Grigoriadis; Sarah McDonald; Kerry Fenwick; Alan Mackay; Charles A Mein; Rachael Natrajan; Kay Savage; Narinder Tamber; Jorge S Reis-Filho; Nicholas C Turner; Alan Ashworth
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

9.  Cdc25 and Wee1: analogous opposites?

Authors:  Jennifer A Perry; Sally Kornbluth
Journal:  Cell Div       Date:  2007-05-04       Impact factor: 5.130

10.  AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.

Authors:  James B Ford; Dmitry Baturin; Tamara M Burleson; Annemie A Van Linden; Yong-Mi Kim; Christopher C Porter
Journal:  Oncotarget       Date:  2015-09-29
View more
  6 in total

1.  Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.

Authors:  Dongshao Chen; Xiaoting Lin; Jing Gao; Lin Shen; Zhongwu Li; Bin Dong; Cheng Zhang; Xiaotian Zhang
Journal:  Biomed Res Int       Date:  2018-06-07       Impact factor: 3.411

2.  Inhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma.

Authors:  Meng-Ling Yuan; Pei Li; Zi-Hao Xing; Jin-Ming Di; Hui Liu; An-Kui Yang; Xi-Jun Lin; Qi-Wei Jiang; Yang Yang; Jia-Rong Huang; Kun Wang; Meng-Ning Wei; Yao Li; Jin Ye; Zhi Shi
Journal:  Front Pharmacol       Date:  2018-09-28       Impact factor: 5.810

3.  Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.

Authors:  Christoph Lübbehüsen; Julian Lüke; Carolin Seeling; Kevin Mellert; Ralf Marienfeld; Alexandra von Baer; Markus Schultheiss; Peter Möller; Thomas F E Barth
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

4.  Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo.

Authors:  Shuning Bi; Qiuren Wei; Zhijun Zhao; Liang Chen; Chaojie Wang; Songqiang Xie
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

5.  Long non-coding RNA LINC00511 facilitates colon cancer development through regulating microRNA-625-5p to target WEE1.

Authors:  Xiaowu Qian; Chun Jiang; Zhengtai Zhu; Gaohua Han; Ning Xu; Jun Ye; Ruixing Wang
Journal:  Cell Death Discov       Date:  2022-04-27

6.  Down-regulation of EGFL8 regulates migration, invasion and apoptosis of hepatocellular carcinoma through activating Notch signaling pathway.

Authors:  Fan Wu; Fang-Yong Zhang; Guo-Qian Tan; Wei-Jia Chen; Biao Huang; Lun Yan; Hao-Lu Zhang; Shi Chen; Yang Jiao; Bai-Lin Wang
Journal:  BMC Cancer       Date:  2021-06-15       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.